These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26135220)

  • 21. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients.
    Miyake Y; Shouzu A; Nishikawa M; Yonemoto T; Shimizu H; Omoto S; Hayakawa T; Inada M
    Arzneimittelforschung; 1999 Apr; 49(4):324-9. PubMed ID: 10337451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypercholesterolemia and 3-hydroxy 3-methylglutaryl Coenzyme A reductase regulation during ageing.
    Trapani L; Pallottini V
    ScientificWorldJournal; 2009 Jul; 9():564-74. PubMed ID: 19578714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insight into the mechanism of polyphenols on the activity of HMGR by molecular docking.
    Islam B; Sharma C; Adem A; Aburawi E; Ojha S
    Drug Des Devel Ther; 2015; 9():4943-51. PubMed ID: 26357462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From fungus to pharmaceuticals--the chemistry of statins.
    McPherson PA
    Mini Rev Med Chem; 2012 Oct; 12(12):1250-60. PubMed ID: 22512563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. QSAR & complex network study of the HMGR inhibitors structural diversity.
    García I; Diop YF; Gómez G
    Curr Drug Metab; 2010 May; 11(4):307-14. PubMed ID: 20446903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The activity of HMG-CoA reductase and acetyl-CoA carboxylase in human apocrine sweat glands, sebaceous glands, and hair follicles is regulated by phosphorylation and by exogenous cholesterol.
    Smythe CD; Greenall M; Kealey T
    J Invest Dermatol; 1998 Jul; 111(1):139-48. PubMed ID: 9665401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani.
    Singh S; Dinesh N; Kaur PK; Shamiulla B
    Parasitol Res; 2014 Jun; 113(6):2161-8. PubMed ID: 24728519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sex differences in hepatic regulation of cholesterol homeostasis.
    De Marinis E; Martini C; Trentalance A; Pallottini V
    J Endocrinol; 2008 Sep; 198(3):635-43. PubMed ID: 18603607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3-Hydroxy-3-methylglutaryl coenzyme A reductase regulation by antioxidant compounds: new therapeutic tools for hypercholesterolemia?
    Trapani L; Segatto M; Incerpi S; Pallottini V
    Curr Mol Med; 2011 Dec; 11(9):790-7. PubMed ID: 21999146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One statin, two statins, three statins, more: similarities and differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Turkoski BB
    Orthop Nurs; 2011; 30(1):62-5; quiz 66-7. PubMed ID: 21278557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential.
    Ahmad S; Madsen CS; Stein PD; Janovitz E; Huang C; Ngu K; Bisaha S; Kennedy LJ; Chen BC; Zhao R; Sitkoff D; Monshizadegan H; Yin X; Ryan CS; Zhang R; Giancarli M; Bird E; Chang M; Chen X; Setters R; Search D; Zhuang S; Nguyen-Tran V; Cuff CA; Harrity T; Darienzo CJ; Li T; Reeves RA; Blanar MA; Barrish JC; Zahler R; Robl JA
    J Med Chem; 2008 May; 51(9):2722-33. PubMed ID: 18412317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin.
    Trapani L; Segatto M; Simeoni V; Balducci V; Dhawan A; Parmar VS; Prasad AK; Saso L; Incerpi S; Pallottini V
    Biochimie; 2011 Jul; 93(7):1165-71. PubMed ID: 21530605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Some effects of chitosan on liver function in the rat.
    LeHoux JG; Grondin F
    Endocrinology; 1993 Mar; 132(3):1078-84. PubMed ID: 7679967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer.
    Wei TT; Lin YT; Chen WS; Luo P; Lin YC; Shun CT; Lin YH; Chen JB; Chen NW; Fang JM; Wu MS; Yang KC; Chang LC; Tai KY; Liang JT; Chen CC
    EBioMedicine; 2016 Aug; 10():124-36. PubMed ID: 27448759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels.
    Kumai T; Matsumoto N; Koitabashi Y; Takeba Y; Oonuma S; Sekine S; Tadokoro M; Kobayashi S
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Jul; 3(3):195-201. PubMed ID: 15974884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
    Chen JB; Chern TR; Wei TT; Chen CC; Lin JH; Fang JM
    J Med Chem; 2013 May; 56(9):3645-55. PubMed ID: 23570542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluvastatin and fluvastatin extended release: a clinical and safety profile.
    Asberg A; Holdaas H
    Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):641-52. PubMed ID: 15350166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
    Zhang QY; Wan J; Xu X; Yang GF; Ren YL; Liu JJ; Wang H; Guo Y
    J Comb Chem; 2007; 9(1):131-8. PubMed ID: 17206841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
    Martin G; Duez H; Blanquart C; Berezowski V; Poulain P; Fruchart JC; Najib-Fruchart J; Glineur C; Staels B
    J Clin Invest; 2001 Jun; 107(11):1423-32. PubMed ID: 11390424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.